Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week, , on November 9, 2020 at 11:27 pm

By
On November 9, 2020
Tags:

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of November 2nd – 8th, 2020.Without further ado, let’s get started.* Yahoo Finance readers, please click here to view the full article.10. Cannabis Stocks Go Bonkers as 2020 U.S. Election Brings Massive Green WaveThe 2020 U.S. Election Saw 5 New States Approve Marijuana Legalization Measures, Which New Frontier Data Expects Could Grow the Size of the Cannabis Industry By an Estimated $9 BillionDespite some lingering uncertainty surrounding the race for the Presidency between President Donald Trump and former Vice President Joe Biden, cannabis investors arguably walked away from this year’s election as the biggest winners, as evidenced by U.S. and Canadian Pot Stocks’ week of blistering gains.READ FULL CANNABIS ELECTION ARTICLE9. This Psychedelic Stock Was a Winner on Election NightVoters in Oregon Approved a Ballot Measure That Legalizes a Treatment This Newly Public Company Has in Clinical TrialsBiotech startup Compass Pathways (NASDAQ: CMPS) got good news in the U.S. election last night when Oregon became the first state in the nation to legalize the use of psilocybin — the active ingredient in Psychedelic mushrooms — as a therapeutic treatment in mental healthcare.READ FULL COMPASS PATHWAYS ARTICLE8. Aphria’s Deal to Buy SweetWater Brewing is a Good One, Says HaywoodHaywood Capital Markets Analyst Neal Gilmer Likes the New Craft Brewer Acquisition in the United States By Cannabis Company AphriaIn an update to clients, the analyst stated that the deal adds diversification to Aphria’s NYSE: APHA) lineup ahead of the potential legalization of cannabis in the US. The deal is valued at approximately $300 million including $250 million in cash and the rest in stock, along with up to $66 million in additional cash earnouts up to 2023.READ FULL APHRIA ARTICLE7. Havn Life Sciences CEO on Decriminalization of Psychedelics in Oregon and Washington D.C.DC’s Initiative 81 Passed, Decriminalizing a Wide Range of Psychedelics and Oregonians Voted in Favor of Measure 109, Allowing Patients 21-and-Over to Buy, Possess, and Consume Psychedelic Drugs at “Psilocybin Service Centers”Havn Life Sciences (CSE: HAVN) CEO Tim Moore joined The Dales Report to discuss the recent news last week concerning the U.S. Election and the decriminalization of Psychedelic drugs in both Oregon and Washington D.C.READ FULL HAVN LIFE ARTICLE6. Aurora Cannabis’ Revenues Fall 6% To $67.8 Million In Q1 2021, Net Loss Hits $109.5 MillionNet Revenue Fell on a Quarterly Basis From $72.1M to $67.8M, a Function of Both Discontinued Operations in Aurora Hemp Europe and Aurora Larssen Projects, as Well as Declining Cannabis SalesWhereas Canopy Growth (NYSE: CGC) posted revenue growth of 22.5% this morning on a quarter over quarter basis, Aurora Cannabis (NYSE: ACB) continued to give up its lead, with Aurora revenues declining 5.96% on a quarterly basis. Aurora’s net revenues hit $67.8 million, while the net loss amounted to $109.5 million.READ FULL AURORA CANNABIS ARTICLE5. Field Trip Health Prepares to Enter Oregon Market following the Passage of Measure 109 in Oregon, Creating the First Legal Market for Psilocybin ServicesField Trip is Rolling Out Field Trip Health Centers for the Delivery of Psychedelic Therapies, is Positioned Be a Leader in the Emerging Psychedelic RenaissanceField Trip Health (OTC: FTRPF), one of the leaders in the development and delivery of Psychedelic therapies, announced today that it is in the advanced stages of identifying potential sites for Field Trip Health centers to treat people in Oregon with Psilocybin therapies following the passage of Measure 109.READ FULL FIELD TRIP ARTICLE4. Canopy Growth’s Net Revenue Climbs 22.5% to $135.3 Million in Q2, Records Loss of $96.6 MillionThe Company’s Revenue Growth Came Largely From Canadian Recreational Net Revenue, Which Rose From $44.2 Million to $60.9 Million During the QuarterCanopy Growth (NYSE: CGC) reported its second-quarter 2021 Earnings, reporting net revenues of $135.3 million along with a net loss of $96.6 million for the period ended September 30, 2020. Revenues were up significantly on a quarter over quarter basis, with growth amounting to 22.5%.READ FULL CANOPY GROWTH ARTICLE3. How a Decriminalization Vote is Making Psychedelics Investors a Lot of MoneyAnd So it Begins. On Election Night, Washington, D.C., and Oregon Voted to Decriminalize PsychedelicsMore than a dozen publicly traded Psychedelic Stocks, and literally hundreds of millions of dollars now flowing into Psychedelics startups. I’ve personally done quite well with some of these, particularly MindMed (OTCQB: MMEDF), which has already more than doubled my initial investment. And honestly, this market is only now starting to really heat up.READ FULL PSYCHEDELICS INVESTORS2. Curaleaf Completes Purchase of ATG’s Massachusetts Facilities, Sells Maryland AssetsThe Acquisition Agreement, Confirmed Thursday, Was First Signed Back in August of 2018Cannabis company Curaleaf (OTCQX: CURLF) finalized the purchase transaction of Alternative Therapies Group’s licensed cultivation and processing facility in Amesbury, Massachusetts.READ FULL CURALEAF ARTICLE1. MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSDData to Support MindMed’s Project Lucy in Preparing Phase 2b Trial for Anxiety DisordersMindMed (OTCQB: MMEDF) the leading Psychedelic medicine biotech company in partnership with University Hospital Basel’s Liechti Lab announces the completion and publication of a Phase 1 study on the acute dose dependent effects of LSD. The completed Phase 1 study will help MindMed in dose-finding and the planning of future Phase 2 clinical trials of LSD in patients with anxiety disorders and other medical conditions.READ FULL MINDMED ARTICLEPhoto by Matthew Brodeur on UnsplashSee more from Benzinga * Click here for options trades from Benzinga * Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week * Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.,

Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The WeekWelcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of November 2nd – 8th, 2020.Without further ado, let’s get started.* Yahoo Finance readers, please click here to view the full article.10. Cannabis Stocks Go Bonkers as 2020 U.S. Election Brings Massive Green WaveThe 2020 U.S. Election Saw 5 New States Approve Marijuana Legalization Measures, Which New Frontier Data Expects Could Grow the Size of the Cannabis Industry By an Estimated $9 BillionDespite some lingering uncertainty surrounding the race for the Presidency between President Donald Trump and former Vice President Joe Biden, cannabis investors arguably walked away from this year’s election as the biggest winners, as evidenced by U.S. and Canadian Pot Stocks’ week of blistering gains.READ FULL CANNABIS ELECTION ARTICLE9. This Psychedelic Stock Was a Winner on Election NightVoters in Oregon Approved a Ballot Measure That Legalizes a Treatment This Newly Public Company Has in Clinical TrialsBiotech startup Compass Pathways (NASDAQ: CMPS) got good news in the U.S. election last night when Oregon became the first state in the nation to legalize the use of psilocybin — the active ingredient in Psychedelic mushrooms — as a therapeutic treatment in mental healthcare.READ FULL COMPASS PATHWAYS ARTICLE8. Aphria’s Deal to Buy SweetWater Brewing is a Good One, Says HaywoodHaywood Capital Markets Analyst Neal Gilmer Likes the New Craft Brewer Acquisition in the United States By Cannabis Company AphriaIn an update to clients, the analyst stated that the deal adds diversification to Aphria’s NYSE: APHA) lineup ahead of the potential legalization of cannabis in the US. The deal is valued at approximately $300 million including $250 million in cash and the rest in stock, along with up to $66 million in additional cash earnouts up to 2023.READ FULL APHRIA ARTICLE7. Havn Life Sciences CEO on Decriminalization of Psychedelics in Oregon and Washington D.C.DC’s Initiative 81 Passed, Decriminalizing a Wide Range of Psychedelics and Oregonians Voted in Favor of Measure 109, Allowing Patients 21-and-Over to Buy, Possess, and Consume Psychedelic Drugs at “Psilocybin Service Centers”Havn Life Sciences (CSE: HAVN) CEO Tim Moore joined The Dales Report to discuss the recent news last week concerning the U.S. Election and the decriminalization of Psychedelic drugs in both Oregon and Washington D.C.READ FULL HAVN LIFE ARTICLE6. Aurora Cannabis’ Revenues Fall 6% To $67.8 Million In Q1 2021, Net Loss Hits $109.5 MillionNet Revenue Fell on a Quarterly Basis From $72.1M to $67.8M, a Function of Both Discontinued Operations in Aurora Hemp Europe and Aurora Larssen Projects, as Well as Declining Cannabis SalesWhereas Canopy Growth (NYSE: CGC) posted revenue growth of 22.5% this morning on a quarter over quarter basis, Aurora Cannabis (NYSE: ACB) continued to give up its lead, with Aurora revenues declining 5.96% on a quarterly basis. Aurora’s net revenues hit $67.8 million, while the net loss amounted to $109.5 million.READ FULL AURORA CANNABIS ARTICLE5. Field Trip Health Prepares to Enter Oregon Market following the Passage of Measure 109 in Oregon, Creating the First Legal Market for Psilocybin ServicesField Trip is Rolling Out Field Trip Health Centers for the Delivery of Psychedelic Therapies, is Positioned Be a Leader in the Emerging Psychedelic RenaissanceField Trip Health (OTC: FTRPF), one of the leaders in the development and delivery of Psychedelic therapies, announced today that it is in the advanced stages of identifying potential sites for Field Trip Health centers to treat people in Oregon with Psilocybin therapies following the passage of Measure 109.READ FULL FIELD TRIP ARTICLE4. Canopy Growth’s Net Revenue Climbs 22.5% to $135.3 Million in Q2, Records Loss of $96.6 MillionThe Company’s Revenue Growth Came Largely From Canadian Recreational Net Revenue, Which Rose From $44.2 Million to $60.9 Million During the QuarterCanopy Growth (NYSE: CGC) reported its second-quarter 2021 Earnings, reporting net revenues of $135.3 million along with a net loss of $96.6 million for the period ended September 30, 2020. Revenues were up significantly on a quarter over quarter basis, with growth amounting to 22.5%.READ FULL CANOPY GROWTH ARTICLE3. How a Decriminalization Vote is Making Psychedelics Investors a Lot of MoneyAnd So it Begins. On Election Night, Washington, D.C., and Oregon Voted to Decriminalize PsychedelicsMore than a dozen publicly traded Psychedelic Stocks, and literally hundreds of millions of dollars now flowing into Psychedelics startups. I’ve personally done quite well with some of these, particularly MindMed (OTCQB: MMEDF), which has already more than doubled my initial investment. And honestly, this market is only now starting to really heat up.READ FULL PSYCHEDELICS INVESTORS2. Curaleaf Completes Purchase of ATG’s Massachusetts Facilities, Sells Maryland AssetsThe Acquisition Agreement, Confirmed Thursday, Was First Signed Back in August of 2018Cannabis company Curaleaf (OTCQX: CURLF) finalized the purchase transaction of Alternative Therapies Group’s licensed cultivation and processing facility in Amesbury, Massachusetts.READ FULL CURALEAF ARTICLE1. MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSDData to Support MindMed’s Project Lucy in Preparing Phase 2b Trial for Anxiety DisordersMindMed (OTCQB: MMEDF) the leading Psychedelic medicine biotech company in partnership with University Hospital Basel’s Liechti Lab announces the completion and publication of a Phase 1 study on the acute dose dependent effects of LSD. The completed Phase 1 study will help MindMed in dose-finding and the planning of future Phase 2 clinical trials of LSD in patients with anxiety disorders and other medical conditions.READ FULL MINDMED ARTICLEPhoto by Matthew Brodeur on UnsplashSee more from Benzinga * Click here for options trades from Benzinga * Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week * Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road
#12-01 Capital Tower
Singapore 068912

New York

Coming Soon!

Dubai

Coming Soon!

Market Coverage